NurExone (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone") is a pioneering biopharmaceutical company developing regenerative medicine therapies.
For a quick catch up on NRX, here are...
RenovoRx’s TAMP™ platform significantly increases local tissue concentration of chemotherapy, potentially reducing systemic side effects and enhancing treatment efficacy.
The Phase III TIGeR-PaC clinical trial...
("RenovoRx" or the "Company") (Nasdaq: RNXT), is a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform.
Recently, the Company announced the...
NurExone (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone") is a pioneering biopharmaceutical company developing regenerative medicine therapies.
For a quick catch up on NRX, here are...
Nurexone Biologic Inc. leads the charge in developing cutting-edge exosome-based therapies for central nervous system injuries, particularly traumatic spinal cord injuries (tSCI), promising groundbreaking...